The effect of BRAF mutation on the response to anti‐PD1 therefore may be considered when choosing between adjuvant anti‐PD1 and BRAFi/MEKi for patients with BRAF V600 mutant melanoma. The gene discussed is BRAF; the disease is melanoma.